355 related articles for article (PubMed ID: 10964781)
1. Identification of efficiently cleaved substrates for HIV-1 protease using a phage display library and use in inhibitor development.
Beck ZQ; Hervio L; Dawson PE; Elder JH; Madison EL
Virology; 2000 Sep; 274(2):391-401. PubMed ID: 10964781
[TBL] [Abstract][Full Text] [Related]
2. Peptides derived from HIV-1 Vif: a non-substrate based novel type of HIV-1 protease inhibitors.
Friedler A; Blumenzweig I; Baraz L; Steinitz M; Kotler M; Gilon C
J Mol Biol; 1999 Mar; 287(1):93-101. PubMed ID: 10074409
[TBL] [Abstract][Full Text] [Related]
3. Hydrophilic peptides derived from the transframe region of Gag-Pol inhibit the HIV-1 protease.
Louis JM; Dyda F; Nashed NT; Kimmel AR; Davies DR
Biochemistry; 1998 Feb; 37(8):2105-10. PubMed ID: 9485357
[TBL] [Abstract][Full Text] [Related]
4. Molecular basis of resistance to HIV-1 protease inhibition: a plausible hypothesis.
Luque I; Todd MJ; Gómez J; Semo N; Freire E
Biochemistry; 1998 Apr; 37(17):5791-7. PubMed ID: 9558312
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 Vif-derived peptide inhibits drug-resistant HIV proteases.
Blumenzweig I; Baraz L; Friedler A; Danielson UH; Gilon C; Steinitz M; Kotler M
Biochem Biophys Res Commun; 2002 Apr; 292(4):832-40. PubMed ID: 11944889
[TBL] [Abstract][Full Text] [Related]
6. A structural and thermodynamic escape mechanism from a drug resistant mutation of the HIV-1 protease.
Vega S; Kang LW; Velazquez-Campoy A; Kiso Y; Amzel LM; Freire E
Proteins; 2004 May; 55(3):594-602. PubMed ID: 15103623
[TBL] [Abstract][Full Text] [Related]
7. A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance.
Muzammil S; Ross P; Freire E
Biochemistry; 2003 Jan; 42(3):631-8. PubMed ID: 12534275
[TBL] [Abstract][Full Text] [Related]
8. Multidrug resistance to HIV-1 protease inhibition requires cooperative coupling between distal mutations.
Ohtaka H; Schön A; Freire E
Biochemistry; 2003 Nov; 42(46):13659-66. PubMed ID: 14622012
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the substrate envelope hypothesis for inhibitors of HIV-1 protease.
Chellappan S; Kairys V; Fernandes MX; Schiffer C; Gilson MK
Proteins; 2007 Aug; 68(2):561-7. PubMed ID: 17474129
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of human immunodeficiency virus type-1 reverse transcriptase by a novel peptide derived from the viral integrase.
Oz Gleenberg I; Herschhorn A; Goldgur Y; Hizi A
Arch Biochem Biophys; 2007 Feb; 458(2):202-12. PubMed ID: 17257575
[TBL] [Abstract][Full Text] [Related]
11. Identification of a novel peptide substrate of HSV-1 protease using substrate phage display.
O'Boyle DR; Pokornowski KA; McCann PJ; Weinheimer SP
Virology; 1997 Sep; 236(2):338-47. PubMed ID: 9325241
[TBL] [Abstract][Full Text] [Related]
12. Methods for mapping protease specificity.
Diamond SL
Curr Opin Chem Biol; 2007 Feb; 11(1):46-51. PubMed ID: 17157549
[TBL] [Abstract][Full Text] [Related]
13. Crucial amides for dimerization inhibitors of HIV-1 protease.
Bowman MJ; Chmielewski J
Bioorg Med Chem Lett; 2004 Mar; 14(6):1395-8. PubMed ID: 15006369
[TBL] [Abstract][Full Text] [Related]
14. Molecular analysis of the HIV-1 resistance development: enzymatic activities, crystal structures, and thermodynamics of nelfinavir-resistant HIV protease mutants.
Kozísek M; Bray J; Rezácová P; Sasková K; Brynda J; Pokorná J; Mammano F; Rulísek L; Konvalinka J
J Mol Biol; 2007 Dec; 374(4):1005-16. PubMed ID: 17977555
[TBL] [Abstract][Full Text] [Related]
15. Development of pseudopeptide inhibitors of HIV-1 aspartic protease: analysis and tuning of the subsite specificity.
Tossi A; Antcheva N; Romeo D; Miertus S
Pept Res; 1995; 8(6):328-34. PubMed ID: 8838416
[TBL] [Abstract][Full Text] [Related]
16. Functional characterization of the protease of human endogenous retrovirus, K10: can it complement HIV-1 protease?
Towler EM; Gulnik SV; Bhat TN; Xie D; Gustschina E; Sumpter TR; Robertson N; Jones C; Sauter M; Mueller-Lantzsch N; Debouck C; Erickson JW
Biochemistry; 1998 Dec; 37(49):17137-44. PubMed ID: 9860826
[TBL] [Abstract][Full Text] [Related]
17. Active site binding modes of dimeric phloroglucinols for HIV-1 reverse transcriptase, protease and integrase.
Gupta P; Kumar R; Garg P; Singh IP
Bioorg Med Chem Lett; 2010 Aug; 20(15):4427-31. PubMed ID: 20594846
[TBL] [Abstract][Full Text] [Related]
18. Counteracting HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with XV638 and SD146, cyclic urea amides with broad specificities.
Ala PJ; Huston EE; Klabe RM; Jadhav PK; Lam PY; Chang CH
Biochemistry; 1998 Oct; 37(43):15042-9. PubMed ID: 9790666
[TBL] [Abstract][Full Text] [Related]
19. Predicting human immunodeficiency virus protease cleavage sites in proteins by a discriminant function method.
Chou KC; Tomasselli AG; Reardon IM; Heinrikson RL
Proteins; 1996 Jan; 24(1):51-72. PubMed ID: 8628733
[TBL] [Abstract][Full Text] [Related]
20. Dimerization inhibitors of HIV-1 reverse transcriptase, protease and integrase: a single mode of inhibition for the three HIV enzymes?
Camarasa MJ; Velázquez S; San-Félix A; Pérez-Pérez MJ; Gago F
Antiviral Res; 2006 Sep; 71(2-3):260-7. PubMed ID: 16872687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
